GT Biopharma Inc. Common Stock

GTBPNASDAQ • USD
0.37 USD
↗ 0.00 (0.22%)AT CLOSE (11:59 AM EDT)
0.38
↗ 0.00 (1.21%)
POST MARKET (AS OF 06:13 PM EDT)
Post Market
AS OF 06:13 PM EDT
0.38
↗ 0.00 (1.21%)
🔴Market: CLOSED
Open?$0.36
High?$0.39
Low?$0.36
Prev. Close?$0.37
Volume?475.5K
Avg. Volume?595.1K
VWAP?$0.37
Rel. Volume?0.80x
Bid / Ask
Bid?$0.37 × 100
Ask?$0.38 × 300
Spread?$0.01
Midpoint?$0.37
Valuation & Ratios
Market Cap?11.7M
Shares Out?31.6M
Float?7.5M
Float %?70.1%
P/E Ratio?N/A
P/B Ratio?2.02
EPS?-$1.09
Dividend?1.23%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?3.45Strong
Quick Ratio?3.45Strong
Cash Ratio?2.94Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
N/A▾
P/B?
2.02CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
-0.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
-595.3%WEAK▾
ROA?
-425.0%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$4.9M
Related Companies
CGONSLSCMPXMGNXCRISCNTXAPVOELTXIMCRIPHACADLXLOADAGCVMBCAXINBXRPRXCGENAZNCBIO
News
Profile
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Employees
1
Market Cap
11.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.gtbiopharma.com
Listed
2021-02-11
Address
505 MONTGOMERY STREET
SAN FRANCISCO, CA 94111
Phone: (800) 304-9888
MarketsMoversWatchlist